Altre lingue Xeris Biopharma Holdings, Inc.

Azioni

XERS

US98422E1038

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 29/04/2024			Variaz. 5gg	Var. 1 gen.
1,75 ^USD	0,00%		-1,69%	-25,53%

28/03	XERIS BIOPHARMA HOLDINGS, INC. : via al Buy per Oppenheimer	ZM
06/03	Transcript : Xeris Biopharma Holdings, Inc., Q4 2023 Earnings Call, Mar 06, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03/04
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference	02/04
Xeris Biopharma Holdings, Inc.(NasdaqGS:XERS) added to S&P Pharmaceuticals Select Industry Index	18/03
Xeris Biopharma: Q4 Earnings Snapshot	06/03
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q4 Revenue $44.4M, vs. Street Est of $43.6M	06/03
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events	06/03
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital	06/03
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024	06/03
Xeris Refinances its $150 Million Senior Secured Term Loan Facility with Hayfin Capital	06/03
North American Morning Briefing : Stock Futures -2-	06/03
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024	28/02
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference	05/02
Xeris Biopharma Holdings Seeks Acquisitions	11/01
US Equity Markets Close Higher Wednesday as Investors Await Inflation Data	10/01
Sector Update: Health Care Stocks Gain Late Afternoon	10/01
Xeris Biopharma Shares Rise on Licensing Agreement With Amgen	10/01
Xeris Biopharma Shares Climb 12% on Amgen License Agreement	10/01
Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment	10/01
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab	10/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Xeris Biopharma Holdings, Inc.

Azioni

XERS

US98422E1038

Altre lingue

Filtri